Status:

RECRUITING

IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures

Lead Sponsor:

Massachusetts General Hospital

Collaborating Sponsors:

IlluminOss Medical, Inc.

University of Miami

Conditions:

Cancer Metastatic

Trauma

Eligibility:

All Genders

21+ years

Brief Summary

The aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or ...

Detailed Description

The matrix morphology of the tumors in metastatic bone disease (MBD) may be of blastic, lytic, or mixed characteristics. Cancers of purely lytic or mixed blastic-lytic composition are the most concern...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. It is a decision made by the treating surgeon separately from research and prior to mention of the study.
  • Patient is a skeletally mature patient 21 years of age or older (closed epiphyseal plates) who receiving the FDA-approved IlluminOss Pelvic Implant
  • IlluminOss Pelvic Implant is intended to treat pain due to impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis secondary to metastatic malignancy, multiple myeloma, lymphoma, or radiation osteitis or a pelvic fragility fracture in a geriatric patients (age 65 or older)
  • VAS Pain Score ≥ 30 on 0 to 100 scale
  • Exclusion criteria:
  • Patient is uncooperative, or patient incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder)
  • Patient is a prisoner
  • Patient is deemed surgically unfit by the medical oncology service

Exclusion

    Key Trial Info

    Start Date :

    November 18 2021

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ESTIMATED

    End Date :

    December 1 2027

    Estimated Enrollment :

    100 Patients enrolled

    Trial Details

    Trial ID

    NCT04842266

    Start Date

    November 18 2021

    End Date

    December 1 2027

    Last Update

    October 3 2025

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Massachusetts General Hospital

    Boston, Massachusetts, United States, 02114